Clinical Trials Logo

Positron-Emission Tomography clinical trials

View clinical trials related to Positron-Emission Tomography.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05543317 Completed - Tumor, Solid Clinical Trials

68Ga-FAPI-RGD PET/CT for Dual Integrin αvβ3 and FAP-targeted Imaging in Patients With Various Types of Cancer and Compared With 18F-FDG

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

As a new dual receptor (integrin αvβ3 and FAP) targeting PET radiotracer, 68Ga-FAPI-RGD is promising as an excellent imaging agent applicable to various cancers. In this research, we investigate the safety, biodistribution and radiation dosimetry of 68Ga-FAPI-RGD in healthy volunteers. Moreover, we evaluate the potential usefulness of 68Ga-FAPI-RGD positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, and compared with 18F-FDG PET/CT.

NCT ID: NCT05392205 Completed - Tumor, Solid Clinical Trials

Comaprison of 68Ga-FAP-2286 and 18F-FDG PET/CT in Patients With Various Types of Cancer

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

To evaluate the potential usefulness of 68Ga-FAP-2286 positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, and compared with 18F-FDG PET/CT.

NCT ID: NCT04660279 Completed - Clinical trials for Positron-Emission Tomography

Dynamic FDG PET/CT: Optimization and Validation of Data Acquisition

VALIDATE
Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Quantification of the metabolic rate of glucose from Dynamic Whole-Body PET examinations requires measurements of the time course of the radioactivity concentrations in arterial blood by blood sampling, and in the tissue of interest by dynamic PET. Invasive arterial blood sampling cannot be part of a standard examination, and therefore the blood samples need to be replaced by activity concentrations derived from the PET images, usually from small volumes in the descending aorta or left ventricle. Newly developed scanner software (Siemens) allows automated CT-based identification of blood pool regions and extraction of an image-derived blood input function from the corresponding PET data. However, this automated method needs validation, as it could be prone to systematic errors caused by limited spatial resolution, patient movement, and image reconstruction. We will use invasively measured arterial blood samples as a reference for validation of methods to extract non-invasive PET image-derived input functions and quantify any systematic errors that could propagate to the resulting parametric images.

NCT ID: NCT04515368 Completed - Clinical trials for Positron-Emission Tomography

A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity

PETVACC
Start date: June 10, 2016
Phase: N/A
Study type: Interventional

This study forms part of an integrated, multi-study effort to identify potential biomarkers of reactogenicity to vaccines. We have selected PET-CT as it is in routine clinical use and has been serendipitously shown to image lymph nodes and injection site inflammation after immunisation.The study's objectives are exploratory: 1. To methodically characterise relative anatomical distribution and intensity of post-immunisation innate immune activation visualised by PET-CT after immunisation with adjuvanted and non-adjuvanted vaccines. 2. To correlate PET/CT changes with diary card recorded symptoms of reactogenicity.

NCT ID: NCT04291144 Completed - Clinical trials for Dementia With Lewy Bodies

Visualising Cerebral and Peripheral Cholinergic Nerves in Patients With Dementia Lewy Bodies.

Start date: February 1, 2020
Phase:
Study type: Observational

Lewy Body Dementia (DLB) is the second most common type of neurodegenerative dementia and characterized by loss of cholinergic neurons in the cerebrum and possibly also internal organs. A novel tracer, 18F-fluoroethoxybenzovesamicol (18F-FEOBV), binds to the cholinergic vesicle transporter, a protein expressed uniquely in the vesicles of cholinergic pre-synapses. Our aim is to investigate the cholinergic denervation in patients with DLB using 18F-FEOBV. The investigators plan to recruit 30 patients with DLB and 20 healthy controls to extensive cognitive assessment, computed and positron emission topography, magnetic resonance imaging, and samples of blood. The investigators hypothesize that patients with DLB, compared to controls, have decreased cholinergic innervation in cortical and subcortical areas of the brain, intestines and heart, and that the denervation corresponds to symptoms of autonomic and cognitive dysfunction.

NCT ID: NCT04001257 Completed - Glioma Clinical Trials

18F-Fluoro-Ethyl-Tyrosine (FET) Positron Emission Tomography (PET) and Grading Glioma

GLIOFET
Start date: June 17, 2019
Phase:
Study type: Observational

Role of 18F-FET PET for grading gliomas according to 2016 WHO classification: value of quantitative and qualitative data obtained by 18F-FET PET for differentiating low grade glioma (WHO II) versus high grade gliomas (WHO III and IV)

NCT ID: NCT03802123 Completed - Clinical trials for Positron-Emission Tomography

⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for PET/CT in Patients With Metastatic Solid Tumors

iCorrelate
Start date: December 18, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety of repeat doses ⁸⁹Zr-Df-IAB22M2C and to establish the relationship between ⁸⁹Zr-Df-IAB22M2C PET/CT lesion uptake with CD8+ cells by immunohistochemical staining in patients with selected advanced and metastatic solid malignancies who are scheduled to receive standard of care immunotherapy. The study will also evaluate uptake of ⁸⁹Zr-Df-IAB22M2C by PET/CT in patients at baseline and on immunotherapy.

NCT ID: NCT03741231 Completed - Melanoma Clinical Trials

18FDG-PET in Patients With Melanoma or NSCLC Treated With Immunotherapy

IMMUNOPET
Start date: March 1, 2018
Phase:
Study type: Observational

Study the EFS and OS according to 18FDG PET in patients with melanoma or non small cell lung cancer treated by immunotherapy.

NCT ID: NCT03324893 Completed - Clinical trials for Positron-Emission Tomography

FCH PET/MRI Parathyroid Localization

Start date: April 3, 2018
Phase: N/A
Study type: Interventional

A prospective trial comparing the accuracy of [F-18]-FCH PET/MRI to US and 99mTc-MIBI SPECT/CT for pre-operative parathyroid localization in patients with primary hyperparathyroidism

NCT ID: NCT03180060 Completed - Coronary Disease Clinical Trials

Meta-Analysis of Stress Myocardial Perfusion Imaging

Start date: August 3, 2015
Phase: N/A
Study type: Observational

Background: Detection of coronary artery disease (CAD) is important due to its high prevalence and its medical and economic implications. Purpose: A systematic review of the diagnostic performance of stress echocardiography (Echo), SPECT, cardiac magnetic resonance (CMR), CT Perfusion (CTP) and PET versus invasive coronary angiography (ICA) or fractional flow reserve (FFR) using hierarchical summary ROC (HSROC) methods. Data Sources: MEDLINE, EMBASE and SCOPUS for literature published in English or Spanish from January 1970 to December 2015. Study Selection: For inclusion, studies had to meet the Cochrane guidelines, had to evaluate the sensitivity and specificity methods, and use ICA and/or FFR. Only those studies with STARD methodology ≥60% were included. Data Extraction: Ten investigators extracted patient and study characteristics and 4 resolved any disagreements.